Estrella Immunopharma, Inc.
ESLA · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $4 | $0 | $1 |
| G&A Expenses | $1 | $3 | $0 | $0 |
| SG&A Expenses | $2 | $3 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $7 | $2 | $2 |
| Operating Income | -$9 | -$7 | -$2 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $1 | $1 |
| Pre-Tax Income | -$9 | -$7 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$9 | -$7 | -$1 | -$2 |
| % Margin | – | – | – | – |
| EPS | -0.25 | -0.21 | -0.17 | -0.29 |
| % Growth | -19% | -23.5% | 41.4% | – |
| EPS Diluted | -0.25 | -0.21 | -0.17 | -0.29 |
| Weighted Avg Shares Out | 37 | 35 | 6 | 6 |
| Weighted Avg Shares Out Dil | 37 | 35 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$7 | -$1 | -$0 |
| % Margin | – | – | – | – |